Description: Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.
Home Page: www.sunpharma.com
Sun House
Mumbai,
400063
India
Phone:
91 22 4324 4324
Officers
| Name | Title |
|---|---|
| Mr. Dilip Shantilal Shanghvi | MD & Chairman of the Board |
| Mr. Aalok Dilip Shanghvi | Executive VP, Head of Emerging Markets, Global Generics R&D, Business Devp., and Whole Time Director |
| Mr. C. S. Muralidharan ICWA, M.Com | Chief Financial Officer |
| Mr. Davinder Singh | Executive Vice-President of Global Operations |
| Mr. Dheeraj Prasad Sinha BE | EVP & Chief Information Officer |
| Dr. Abhishek Sharma | VP, Head of Investor Relations & Strategic Projects |
| Mr. Anoop Deshpande | Company Secretary & Compliance Officer |
| Mr. Kalyanasundaram Subramanian | Director of Corporate Development |
| Mr. Suresh Kumar Rai | Chief Human Resources Officer |
| Mr. Kirti Wardhaman Ganorkar | Head of India Business |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 26.9542 |
|---|---|
| Trailing PE: | 39.2188 |
| Price-to-Book MRQ: | 6.2656 |
| Price-to-Sales TTM: | 8.6007 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 43000 |